You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

25 Items
Cancer Type: Hematologic, Multiple Myeloma     
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Daratumumab – In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma
ODB - General Benefit
    dexamethasone
Sep 2019
Cancer Type: Hematologic, Myeloproliferative Neoplasms (MPNs)     
Intent: Palliative
Funding:
ODB - General Benefit
    busulfan - oral tablets
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
Jan 2018
Cancer Type: Gynecologic, Vulva     
Intent: Palliative
Jun 2019
Cancer Type: Head and Neck     
Intent: Palliative
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Neoadjuvant, Curative
Jun 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
May 2019
Cancer Type: Hematologic, Leukemia - Hairy Cell, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Jan 2018
Cancer Type: Hematologic, Leukemia - Hairy Cell, Lymphoma - Non-Hodgkin's Low Grade     
Intent: Palliative
Funding:
New Drug Funding Program
    Rituximab in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab - Maintenance Treatment - Lymphoma
Jul 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Palliative
Funding:
New Drug Funding Program
    Vinorelbine - Non-Small Cell Lung Cancer (NSCLC)
May 2019
Cancer Type: Lung, Non-Small Cell     
Intent: Adjuvant
Funding:
New Drug Funding Program
    Vinorelbine - Adjuvant Treatment of Completely Resected Stage II or IIIa Non-Small Cell Lung Cancer
May 2019